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Abstract Cardiac cachexia is a co-morbidity that may
develop in terminal stages of chronic heart failure (CHF).
Up to 15% of ambulatory patients with heart failure are
affected. Over the last decades, cardiac cachexia and
alterations in muscle metabolism in heart disease have
received increasing research interest. This article highlights
some recent studies of cardiac cachexia that were presented
at the annual meeting of the European Society of
Cardiology in September 2010 in Stockholm, Sweden.
Studies presented here were focused on effects of exercise
training and protein degradation, particularly into the role
of the ubiquitin–proteasome complex and its ubiquitin
ligases MuRF-1 and MAFbx. Exercise training in patients
with CHF was found to increase maximal oxygen con-
sumption and to reduce MuRF-1 expression. Lysosomal
muscle degradation does not seem to play a major role in
patients with CHF, however, inflammatory cytokines such
as tumor necrosis factor-a trigger muscle protein degrada-
tion. Other studies found that the serum levels of the
adipokine adiponectin are elevated in patients with CHF
and that these levels may be correlated with muscle mass,
muscle strength in the arms, or with trunk fat mass. Another
study showed that the expression of myostatin in skeletal
muscle, a negative regulator of muscle growth that is
essential for normal regulation of muscle mass, is decreased
in spontaneously hypertensive rats with heart failure
compared with control animals. This is also true for
follistatin, a powerful antagonist, and its potential as a
biomarker of muscle wasting. These findings may pave the
way for effective treatment approaches to cardiac cachexia.
1 Introduction
This year’s meeting of the European Society of Cardiology
(ESC) was held in the beautiful city of Stockholm, Sweden.
With a total of 27,547 registered participants, it is the
largest medical event in the world related to disease of the
heart and the vasculature. Attendance was not as high as
that in Barcelona in 2009, but still 12% above the level
recorded in 2005 when the congress was last held in
Stockholm. With 936 accepted abstracts, German scientists
were the front-runners in scientific presentations (9.8%),
closely followed by Italy (913 abstracts, 9.6%) and Japan
(8.2%). Professor Roberto Ferrari, current president of the
ESC, said that particularly Japanese participation made the
ESC meeting a congress of the world.
Although heart failure is receiving increasing research
interest, cardiac cachexia as its terminal stage remains a
neglected clinical entity, even though between 5% and 15%
of patients with heart failure are affected [1, 2]. Therapeutic
approaches are limited to exercise training [3], nutritional
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remain restricted to clinical studies [7–9]. Some interesting
new studies regarding pathophysiology, treatment, and
prediction of prognosis in cachexia and muscle metabolism
among patients with cardiovascular diseases were presented
at the ESC conference and are summarized here.
2 Exercise and different degradation pathways
Stephan Gielen (Heart Center, University of Leipzig,
Germany) presented data about differential responses of
MuRF-1 and MAFbx expression in skeletal muscle to
training interventions in heart failure patients. Both proteins
are E-3 ubiquitin ligases that covalently bind ubiquitin to
the target protein; hence, their activity is limiting the rate of
protein degradation by the proteolytic ubiquitin–protea-
some system (Fig. 1). The expression of MuRF-1 and
MAFbx is regulated by transcription factors like FOXO and
NF–κB, which makes them inducible by cytokines like
tumor necrosis factor-α (TNFα) or interleukin (IL) 1.
Gielen explained that muscle wasting in chronic heart
failure (CHF) is an independent predictor of mortality, and
it has already been shown that the activation of the
proteolytic ubiquitin–proteasome system is associated with
increased expression of the muscle-specific ubiqitin ligase
MuRF-1 [10]. Substrates of Murf-1 include myosin in
muscle and troponin I in heart and are essential for
ubiquitination and subsequent degradation of myofibrillar
proteins in the course of cachexia [11]. But, it is still
unclear if the second muscle-specific E3-ligase MAFbx is
also involved in the muscle wasting process and how
MuRF-1 and MAFbx respond to endurance training in
patients with CHF of different age groups. Sixty patients
with CHF and 60 healthy controls were randomized to
4 weeks of bicycle ergometer training at 70% of their
respective heart rate reserve 4×20 min/day or to a control
group. Before and after the intervention, spiroergometry,
echocardiography, and a vastus lateralis muscle biopsy were
performed. Expression of the E3 ligases MuRF-1 and MAFbx
as part of the ubiquitin–proteasome system was quantified by
real-time polymerase chain reaction (PCR) standardized for
18S-rRNA and Western blot. In younger CHF patients (n=15,
age 45±3 years, body mass index [BMI] 26.8±2.7, left
ventricular ejection fraction [LVEF] 26.8±2.6%), training
improved maximum oxygen consumption (peak VO2)b y
36% from 13.3±1.6 to 18.1±1.5 mL/min*kg (p=0.008 vs.
control). In elderly CHF patients (n=15, age 68±4 years,
BMI 25.3±2.9, LVEF 27.4±3.0%), increased peak VO2
by 33% from 12.9±1.4 to 17.1±1.1 mL/min*kg (p=0.01
versus control). At baseline, MuRF-1 mRNA expression
in CHF patients was significantly elevated versus healthy
subjects at 624±59 versus 401±25 relative units (p=0.007)
and protein expression at 0.82±0.09 versus 0.57±0.04
relative units (p=0.01). MAFbx expression as measured by
mRNA and Western blot was similar in CHF patients and
healthy subjects and did not change with age. Training
induced a reduction of MuRF-1 expression by 34.3% (p=
0.02) in younger CHF patients and a reduction of 24.3% (p<
0.05) in elderly. MAFbx did not show any significant
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Fig. 1 Protein degradation by
the ubiquitin–proteasome sys-
tem: TNFα stimulation leads to
protein degradation by the
ubiquitin–proteasome complex
and activation of NF–κB. Phos-
phorylation of IκB activates
NF–κB. IκB and the proteins to
be degraded are marked by a
poly-ubiquitin chain. After
ubiquitination, marked proteins
and IκB are degraded by the
proteasome complex. NF–κB
can then signal into the nucleus,
and transcription of the affiliated
gene is induced
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versus 0.8±0.2 relative units; elderly CHF, 0.8±0.1 versus
0.7±0.1 relative units). Gielen concluded that exercise
training improves peak VO2 significantly in both younger
and older patients with CHF and that these results underline
the importance of exercise-based rehabilitation programs to
prevent CHF-related muscle wasting. On a molecular level,
this study confirms that muscle wasting is mediated by
selective activation of MuRF-1. On the other hand, MAFbx
levels seem to remain unchanged by both the disease process
and the training intervention.
In another session, Dr. Gielen also presented results of two
different protein degradation pathways. These pathways were
analyzed in skeletal muscle biopsies of patients with CHF.
Expression of MuRF-1 as part of the ubiquitin–proteasome
system was compared with cathepsin L as a marker of
lysosomal proteolysis. Again, 60 CHF patients and 60 healthy
controls were randomized to 4 weeks of bicycle ergometer
training at 70% of heart rate reserve 4×20 min/day or to a
control group. Before and after the intervention, spiroergom-
etry, echocardiography, measurement of quadriceps force
endurance, and vastus lateralis muscle biopsy wereperformed.
Expression of Murf-1 was quantified by real-time PCR
standardized for 18S-rRNA and Western blot. Cathepsin L
was measured by real-time PCR. In younger CHF patients (n=
15, age 45±3 years, BMI 26.8±2.7, LVEF 26.8±2.6%),
training improved peak VO2 by 23% from 14.7±3.1 to 18.1±
3.0 mL/min*kg (p=0.008 vs. controls) and force endurance
by 47% from 22.8±2.5 to 33.6±2.9 s (p=0.002 vs. control).
In elderly CHF patients (n=15, age 68±4 years, BMI 25.3±
2.9, LVEF 27.4±3.0%), training increased peak VO2 by 17%
from 15.2±2.6 to 17.8±2.4 mL/min*kg (p=0.01 vs. control,
p=0.06 vs. younger trained CHF patients). Force endurance
improved by 44.2% from 23.5±4.2 to 33.9±4.1 s (p=0.01vs.
control, p=NS vs. younger trained CHF patients). Murf-1
mRNA expression at baseline in CHF patients was
significantly elevated vs. healthy controls at 593±68 vs.
410±27 relative units (p=0.013) and protein expression at
0.90±0.08 vs. 0.62±0.05 relative units (p=0.018). Ca-
thepsin L was not different between both groups. Training
induced a reduction in Murf-1 expression by 34.3% (p=
0.02) in younger CHF patients and a reduction of 24.3% in
elderly (p<0.05, p=0.15 vs. younger CHF patients).
Otherwise, cathepsin L expression remained unchanged.
Gielen summarized that muscle wasting in CHF is
mediated via the ubiquitin–proteasome system and that
the lysosomal system does not seem to play a major role in
skeletal muscle. Furthermore, Gielen concluded that
exercise training significantly improves maximum exer-
cise capacity and forced muscular endurance, however, the
relative gain in exercise capacity was slightly attenuated in
elderly patients. We should think of more prolonged or
higher intensive training programs for elderly CHF
patients to achieve the same clinical benefit as compared
with younger patients.
3 Adiponectin
Adiponectin is an anti-inflammatory, insulin-sensitizing,
and anti-atherogenic adipocytokine, which plays a funda-
mental role in energy homeostasis [12]. Adiponectin
comprises 244 amino acids, and it is synthesized and
secreted in large quantities from adipose tissue [13]. The
protein regulates lipid and glucose metabolism at the level
of the skeletal muscle [14]. Low adiponectin levels have
been associated with increased risk for coronary artery
disease [15]. However, this risk does not seem to apply for
the development of CHF [16].
M. van Berendoncks (Department of Medicine, University
of Antwerp, Antwerp, Belgium) presented the results of a study
that investigated whether adiponectin levels in CHF were
associated with muscle mass and function. Ten male patients
with CHF (LVEF 27±4%, mean±standard error of mean) were
compared with seven healthy male controls of similar age and
BMI. All subjects underwent a thorough clinical investigation
including collection of anthropometric data, cardio-pulmonary
exercise testing, measurement of upper and lower limb
strength, and an assessment of their quadriceps muscle cross-
sectional area (CSA) by computerized tomography scanning.
Finally, circulating adiponectin levels were analyzed using
enzyme-linked immunosorbent assay. It could be shown that,
compared with the control group, patients with CHF had
impaired exercise capacity (peak VO2, peak maximal work-
load) and muscle strength (all p<0.01). Whilst quadriceps
CSA was significantly lower in patients with CHF compared
with the control subjects (57.7±4.5 vs. 84.1±5.1 cm
2; p<
0.002), thigh circumference and BMI were similar in the two
groups. Strength/muscle CSA did not differ between groups.
Patients with CHF had significantly higher adiponectin levels
than healthy controls (16.5±5.1 mg/L vs. 4.6±0.7 mg/L; p=
0.025). Adiponectin levels were negatively correlated with
thigh circumference (r=−0.665; p=0.036), quadriceps
strength (r=−0.670; p=0.048), and quadriceps muscle CSA
(r=−0.673; p=0.033). In addition, a negative correlation was
also apparent between adiponectin and muscle strength of the
upper limbs (r=−0.892; p=0.003) and muscle mass expressed
as difference in median arm circumference during contraction
and relaxation (r=−0.739; p=0.015). Van Berendoncks
concluded that high adiponectin levels in patients with CHF
are associated with decreased muscle mass and impaired
muscle strength and that these results corroborate the
hypothesis that adiponectin may be a marker of muscle
wasting in CHF.
Another study regarding adiponectin as a marker of
cardiac functional class and impaired energy metabolism in
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Tibor Szabó (Department of Cardiology, Charite Medical
School, Berlin, Germany). Szabó et al. assessed circulating
adiponectin levels in 181 stable CHF patients and 35
healthy controls of similar age and BMI. Detailed analysis
of body composition was performed by dual energy X-ray
absorbtiometry; insulin sensitivity was assessed by Homeo-
stasis Model Assessment (HOMA) and exercise capacity by
spiroergometry. A total of 164 patients suffered from CHF
with reduced ejection fraction (LVEF 36±1%, peak VO2
18.0±0.5 mL/min*kg) and 17 patients from CHF with
preserved ejection fraction (LVEF 33±4%, peak VO2
21.2±1.3 mL/min*kg). In patients, plasma adiponectin
concentrations increased stepwise with increasing New York
Heart Association functional class (I/II/III, 8.3±1.2/10.2±
0.9/17.5±2.1 mg/dL; ANOVA p<0.001) and discriminated
cachectic from non-cachectic CHF patients (17.9±3.4 vs.
11.7±0.7 mg/dL; p=0.01). Commonly observed gender
differences were confirmed in controls (female/male, 13.6±
1.9/9.3±0.9 mg/dL; p<0.05) but were not detectable in
patients with CHF (p>0.9). Adiponectin levels correlated
inversely with BMI (r=−0.31, p<0.001) and specifically
with trunk fat tissue (percent fat, r=−0.40; p<0.001). In
addition, patients with CHF were found to have impaired
insulin sensitivity compared with controls (HOMA, 3.0±0.2
vs. 1.5±0.2 p<0.001), and adiponectin correlated weakly
with HOMA (r=−0.21, p=0.01). Correlations for high-
density lipoprotein (HDL) cholesterol and triglycerides were
less pronounced in patients with CHF compared with
controls (r=0.61 vs. 0.36 and r=−0.41 vs. −0.26, all p<
0.05). Furthermore, adiponectin correlated with peakVO2,
O2 at anaerobic threshold and slope (r=−0.20; −0.30; 0.36;
all p<0.05). Szabó concluded that elevated adiponectin
levels were significantly associated with advanced disease
state, symptomatic status, and metabolic impairment. The
alleviated relation between adiponectin versus triglyceride
and HDL concentrations in CHF patients may contribute to
the development of insulin resistance, unfavorable energy
efficiency, and elevated risk profile in this population.
4 Myogenic transcription factors, myostatin,
and follistatin
Ricardo L. Damatto (Department of Internal Medicine, Sao
Paulo State University, Botucatu Medical School, Botucatu,
Brazil) explained in his presentation that changes in myosin
heavy-chain isoforms and muscle atrophy have been fre-
quently observed in patients with heart failure. Damatto
presented a study testing the hypothesis that skeletal muscle
phenotype changes are related to myogenic regulatory factors
like myogenin, MyoD, and myogenic regulatory factor 4
(MRF4) and myostatin or follistatin expression in spontane-
ously hypertensive rats with heart failure. Myogenin, MyoD,
and MRF4 are muscle-specific transcription factors, which
belong to a large family of basic helix–loop–helix proteins.
These factors were first isolated in the 1980s [17]. Myostatin,
also known as growth differentiation factor-8, is expressed
almost exclusively in skeletal muscle. It is a negative
regulator of muscle growth and essential for normal
regulation of muscle mass [18]. Under normal conditions,
myostatin inhibits myoblast proliferation and thus acts as a
negative regulator of muscle bulk [19]. Follistatin has
emerged as a powerful antagonist of myostatin that can
increase muscle mass and strength [20]. Several studies that
support this approach demonstrate the potential of blocking
the myostatin pathway [21] and may therefore represent an
interesting therapeutic avenue to cachexia treatment (Fig. 2).
Damatto and colleagues investigated 18-month-old
spontaneously hypertensive rats (SHR) twice weekly to
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Fig. 2 Myostatin pathway: myo-
statin levels regulate skeletal
muscle cell homeostasis. Myosta-
tin is synthesized and secreted by
muscle cell; it signals through the
activin receptor IIB/ALK4/5 het-
erodimer to activate different
pathways including Smad2/3 and
MAPK (ERK1/2, p38MAPK)
resulting in the regulation of gene
expression. Myostatin stimulation
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features of heart failure. After the detection of heart failure,
animals underwent transthoracic echocardiogram and were
subsequently euthanized on the following day. During
euthanasia, pathological evidence of heart failure such as
pleuropericardial effusion, ascites, left atrial thrombi, right
ventricular hypertrophy, and lung congestion were
recorded. Age-matched Wistar-Kyoto (WKY) rats were
used as controls. Soleus muscle morphometry was analyzed
in hematoxylin and eosin and picro-sirius red stained
sections, and myosin heavy-chain (MyHC) isoforms were
evaluated by protein electrophoresis. Myogenic regulatory
factors, myogenin, MyoD, and MRF4, and myostatin and
follistatin protein levels were analyzed by Western blot.
All spontaneously hypertensive rats presented tachypnea
and right ventricular hypertrophy. Other heart failure
evidence had frequencies between 38% and 88%. None of
the Wistar-Kyoto control rats presented any evidence of
heart failure. Echocardiographic evaluation showed left
chamber dilation, left ventricular hypertrophy, and left
ventricular systolic and diastolic dysfunction in those rats
with hypertension. Soleus weight was lower in SHR than in
control animals (p<0.001). Fiber cross-sectional areas were
lower (WKY 3,615±412; SHR 2,035±224 μm
2; p<0.001),
and collagen fractional area was higher (WKY 2.61±0.39;
SHR 4.88±0.98%; p<0.001) in hypertensive rats. Protein
electrophoresis showed decreased IIa MyHC isoform
expression in SHR. Myogenin, myostatin, and follistatin
protein expression was lower in SHR than in control
animals. MyoD protein expression was similar in both
groups and MRF4 was higher in SHR. Myogenin and
follistatin expression positively correlated with fiber cross-
sectional areas, and MRF4 expression negatively correlated
with IIa MyHC isoform. Damatto concluded that, while
reduced myogenin and follistatin protein expression partic-
ipates in muscle atrophy, increased MRF4 protein expres-
sion modulates myosin heavy-chain isoform shift in skeletal
muscle of spontaneously hypertensive rats with heart
failure.
5 Inflammation
It has been known since the 1990s that elevated levels of
pro-inflammatory cytokines are present in patients with
cardiac cachexia [22]. In one of the first studies, Levine et
al. had demonstrated elevated serum levels of TNFα in
affected patients; not only serum levels of TNFα are
elevated but also those of its soluble receptors 1 and 2
(sTNFR-1 and sTNFR-2), all of which are associated with
poor survival in heart failure [23].
Norman Mangner (Heart Center, University of Leipzig,
Leipzig, Germany) presented data about the force reduction
in the diaphragm of mice mediated via TNFα.T h e
signaling pathway of TNFα through NF–κBa n dt h e
degradation of proteins by the ubiquitin–proteasome system
are shown in Fig. 1. In his introduction, Mangner explained
that TNFα induces the expression of atrogin-like muscle-
specific ubiquitin E3-ligases in skeletal muscle, presumed
to mediate the onset of muscle atrophy. The influence of
TNFα on muscle function in respiratory muscles, e. g.,
diaphragm is not well understood. Therefore, Mangner et
al. examined the influence of TNFα on muscle function and
the expression of MuRF1 in diaphragm of female and male
mice. TNFα (100 ng/g body weight) or saline were injected
into the peritoneum of C57Bl6 mice of either sex (n=10 per
group). After 16–24 h, the expression of MuRF1 in the
diaphragm was quantified using real-time PCR. Muscle
function was measured in an organ bath. Force and power
generation were determined in diaphragm bundles. Results
were adjusted to muscle cross-sectional area, which was
calculated by dividing diaphragm strip weight by strip
length times specific density. Animals injected with TNFα
showed no higher MuRF1 mRNA expression in diaphragm
than saline-injected littermates (saline female vs. TNFα
female, 8.5±1.9 vs. 8.4±2.5 arb. units; saline male vs.
TNFα male, 5.4±0.7 vs. 7.3±1.1 units). TNFα reduced
force development at 150 Hz by ~50% in C57Bl6 animals
(saline female vs. TNFα female, 10.3±1.3 vs. 5.2±1.1 N/
cm
2; p=0.01). Also, maximum power was reduced in
female animals injected with TNFα as compared with sham
injected littermates (saline female vs. TNFα female, 42.0±
6.7 vs. 19.9±5.9 Watt, p<0.03). In male mice, no force or
power reduction was detectable under TNFα exposure.
Mangner concluded that the results of this study demon-
strate, for the first time, a gender-specific force reduction of
the diaphragm after TNFα administration. Mangner men-
tioned that they were previously able to show that TNFα
leads to an induction of MuRF1 and a consecutive
ubiquitination of troponin T accompanied by impaired
muscle function in soleus muscle. In contrast, MuRF1
seems not to be essential for the TNFα-induced force
reduction in the diaphragm of female mice.
Another study regarding possible anti-inflammatory
effects of HDL cholesterol to improve insulin sensitivity
in human skeletal muscle was presented by Bronwyn A.
Kingwell (Baker IDI Heart and Diabetes Institute, Mel-
bourne, Australia). Kingwell said, recent studies indicate
that HDL reduces blood glucose through multiple actions
including enhanced insulin secretion and increased glucose
uptake into skeletal muscle. The responsible pathway is the
AMP-activated protein kinase signaling pathway [24].
Kingwell et al. tested the hypothesis that HDL may
improve insulin sensitivity via lipid removal and anti-
inflammatory actions in macrophages associated with
excess adiposity/ectopic lipid deposition. A variety of
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cell line, the human monocytic cell line THP-1 and primary
human macrophages from healthy participants were incu-
bated separately with lipid challenges including palmitate
(0.5 mM) and acetylated low-density lipoprotein (LDL,
100 μg/mL), then co-treated with either HDL (50 μg/mL)
or vehicle (18 h). Macrophage cultures were subsequently
incubated in fresh media (4 h) and conditioned media (CM)
applied (1:10) to primary human skeletal muscle cell
cultures derived from unmedicated patients with type 2
diabetes mellitus for 24 h and insulin-mediated glucose
uptake (2-deoxy glucose) and insulin signaling (pAkt)
assessed (n=7, all in triplicate). HDL treatment ameliorated
cytokine release (TNFα/IL1β) from macrophages in re-
sponse to lipid challenges by 50% through suppression of
the JNK pathway (39% reduction in JNK phosphorylation).
In skeletal muscle cultures treated with THP-1 CM,
acetylated LDL treatment reduced insulin-mediated glucose
uptake by 31.3±4.1% (p=0.04). Co-treatment with HDL
restored insulin-mediated glucose uptake to control levels
(51.0±13.4% greater than acetylated LDL treatment alone;
p=0.002). Results from two cell lines, the murine RAW cell
line and the human monocytic cell line THP-1 macro-
phages, were recapitulated in primary human macrophages
and demonstrate that HDL-mediated improvements in
skeletal muscle glucose uptake relate to phosphorylation
of the key insulin signaling protein Akt, which in turn
phosphorylates and thereby inactivates negative regulators
of protein synthesis, such as GSK-3 4E-PB or the
transcription factor FOXO, which drives expression of
MuRF-1 and MAFbx. AKT activates protein synthesis by
phosphorylating and activating mTOR and downstream
targets like p70S6K. Kingwell concluded that macrophage
inflammation associated with excess/ectopic adiposity is
reduced by HDL, and these effects may contribute to
improved insulin sensitivity and glucose homeostasis.
These findings, said Kingwell, together with a growing
body of evidence linking HDL to glucose metabolism,
suggest that therapeutics aimed at elevating plasma HDL
levels may provide efficacy in preventing and treating type
2 diabetes. HDL might have beneficial effects as an anti-
inflammatory agent and should be further investigated.
6 Conclusion
Several pathways have been shown to play crucial roles in
muscle wasting in cardiac cachexia. These pathways include
overexpression of MuRF-1, an E3-ubiquitin ligase that
facilitates myofibril degradation via the ubiquitin–proteasome
pathway. Importantly, while this pathway seems to be the
mostimportantoneinmusclewasting,otherpathwayssuchas
the lysosomal cathepsin pathway do not appear to be crucially
involved. The over-activity of inflammatory mediators fuels
the activity of the ubiquitin–proteasome pathway. Exercise
training may have important effects in that it reduces the
expression of MuRF-1. This buttresses the view that exercise
training is beneficial and should be mandated in patients with
heart failure [10]. This is particularly true for patients with
reduced muscle mass and muscle strength; the term
sarcopenia has been suggested for this state, however, its
presence remains underdiagnosed and is usually neglected
by clinicians [25]. The availability of biomarkers to easily
detect muscle loss or even muscle wasting in affected
patients would provide a means for daily clinical practice
to make reaching this diagnosis easier. Adiponectin may
have potential in this regard.
Both cachexia and sarcopenia deserve more attention in
daily clinical work and have not received enough research
endeavors so far. Prospective studies into understanding the
development, phenotype, and the progression of these
perturbations are needed. One such study, the Studies
Investigating Co-morbidities Aggravating Heart Failure
(SICA-HF), is currently ongoing [26]. In the hope that
more research into this area will be presented here, we are
eagerly awaiting the next meeting of the ESC, which will
take place in Paris, France, in August this year.
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